33 Results for "

HTRF

" in MedChemExpress (MCE) Product Catalog:
Products (33)

33 Results for "HTRF" in MCE Product Catalog:

4
4 Cited Publications
Cat. No.: HY-130254
CAS No.: 2380027-49-4
Purity:  98.04%
Target:  

Src

Research Areas:  

Inflammation/Immunology Cancer

CSK-IN-1 (compound 13) is a potent, orally active c-terminal Src kinase (CSK) with IC50 values below 3 nM and 4 nM in CSK HTRF and Caliper assay, respectively. CSK-IN-1 shows the ability to increase T cell proliferation induced by T cell receptor signaling .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-18874
CAS No.: 443913-15-3
Target:  

p38 MAPK Autophagy

Research Areas:  

Others

p38-α MAPK-IN-1 is an inhibitor of MAPK14 (p38-α), with IC50 of 2300 nM in EFC displacement assay, and 5500 nM in HTRF assay .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-134471
CAS No.: 2074702-04-6
Purity:  98.75%
Target:  

TNF Receptor

Research Areas:  

Inflammation/Immunology Cancer

TNF-α-IN-2 is a potent and orally active inhibitor of tumor necrosis factor alpha (TNFα), with an IC50 of 25 nM in the HTRF assay. TNF-α-IN-2 distorts the TNFα trimer upon binding, leading to aberrant signaling when the trimer binds to TNFR1. TNF-α-IN-2 can be used for the research of rheumatoid arthritis .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-153728
CAS No.: 2894832-05-2
Purity:  98.74%
Target:  

WDR5

Research Areas:  

Cancer

WM-586 is a covalent WDR5 inhibitor. WM-586 specifically decreases WDR5 and MYC interaction with an IC50 of 101 nM. WM-586 is used in research on a variety of cancers including neuroblastoma, breast cancer, bladder cancer and colorectal cancer .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-121667
CAS No.: 777857-56-4
Target:  

ROCK

Research Areas:  

Neurological Disease Endocrinology

Scaff10-8 is a RhoA inhibitor. Scaff10-8 binds to RhoA, inhibits AKAP-Lbc-mediated RhoA activation. Scaff10-8 can be used for research on diabetes insipidus and bipolar disorder .
loading...
    loading...
Cat. No.: HY-162664
CAS No.: 3036981-21-9
Target:  

STING

Research Areas:  

Inflammation/Immunology

STING antagonist-1 is an antagonist of STING with an IC50 of 3.8 nM. STING antagonist-1 can be used in the research of autoimmune diseases, inflammatory diseases, and others .
loading...
    loading...
Cat. No.: HY-120635
CAS No.: 2113650-04-5
Purity:  99.32%
Target:  

PD-1/PD-L1

Research Areas:  

Inflammation/Immunology Cancer

BMS-1001 is an orally active human PD-L1/PD-1 immune checkpoint inhibitor. BMS-1001 exhibits low-toxicity in cells. The IC50 value of BMS-1001 in a homogeneous time-resolved fluorescence (HTRF) binding assay is 2.25 nM .
loading...
    loading...
Cat. No.: HY-162275
CAS No.: 861224-48-8
Research Areas:  

Cancer

JMJD1C-IN-1 is an orally active and selective inhibitor of JMJD1C (IC50 = 0.59 μM, Kd = 1.96 μM). JMJD1C-IN-1 inhibits the binding of JMJD1C to H3K9me2 peptide substrate in the HTRF assay (IC50 = 1.47 μM). JMJD1C-IN-1 disrupts intratumoral regulatory T (Treg) cell fitness by dual mechanisms: promoting H3K9me2 accumulation to downregulate PD1 expression and reducing STAT3 demethylation to enhance STAT3 activation. JMJD1C-IN-1 demonstrates dose-dependent antitumor efficacy in multiple mouse tumor models (MCA205 fibrosarcoma, B16-F10 melanoma, LLC lung cancer, Hepa1-6 hepatocellular carcinoma, CT26 colorectal cancer). JMJD1C-IN-1 can be used for the study of tumor immunotherapy by selectively targeting intratumoral Treg cells .
loading...
    loading...
Cat. No.: HY-163759
CAS No.: 3040301-46-7
Target:  

Molecular Glues HuR

Research Areas:  

Cancer

HuR degrader 2 (Compound 3) is a molecule glue, which targets RNA-binding protein Hu antigen R (HuR) and degrades 30% HuR at 0.1 μM. HuR degrader 2 inhibits the proliferation of cancer cell Colo-205, with IC50≤200 nM. HuR degrader 2 exhibits a high affinity with cereblon, with an HTRF ratio < 0.02 .
loading...
    loading...
Cat. No.: HY-16999
CAS No.: 1309684-94-3
Research Areas:  

Cancer

RO8994 (Compound 4) is an orally active, highly potent and selective spiroindolinone p53-MDM2 inhibitor with an IC50 value of 5 nM (HTRF binding assays) and 20 nM (MTT proliferation assays). RO8994 induces up-regulation of p53 expression and Apoptosis in wild-type p53 cancer cells. RO8994 also inhibits tumor growth in the tumor xenograft model .
loading...
    loading...
Cat. No.: HY-158685
CAS No.: 2360561-90-4
Target:  

MDM-2/p53

Research Areas:  

Cancer

RG7112D is a potent MDM2 inhibitor with IC50s of 11 nM and >10000 nM and for MDM2-p53 and VHL-HIF1α by binding HTRF assay, respectively. RG7112D is coupled by an amide bond to VHL-Amine, resulting in a bi-functional molecule, YX-02-030. YX-02-03, a MDM2-PROTAC, potently inhibits MDM2-p53 binding (HTRF IC50=63nM). RG7112D can stabilize MDM2 protein and increase p53 protein levels .
loading...
    loading...
Cat. No.: HY-120647
CAS No.: 2113650-03-4
Target:  

PD-1/PD-L1

Research Areas:  

Inflammation/Immunology Cancer

BMS-1001 is an orally active human PD-L1/PD-1 immune checkpoint inhibitor. BMS-1001 exhibits low-toxicity in cells. The IC50 value of BMS-1001 in a homogeneous time-resolved fluorescence (HTRF) binding assay is 2.25 nM .
loading...
    loading...
Cat. No.: HY-12577
CAS No.: 1498300-31-4
Target:  

PARP

Research Areas:  

Cancer

TNKS1/2-IN-1 (Example 4) is a TNKS1 and TNKS2 inhibitor, with pIC50 values of 8.2 or 7.3 against TNKS1, and 7.1 or 7.7 against TNKS2. TNKS1/2-IN-1 inhibits the enzymatic activities of TNKS1 and TNKS2. TNKS1/2-IN-1 is applicable for cancer research .
loading...
    loading...
Cat. No.: HY-179414
CAS No.: 3102130-17-3
Target:  

Ras

Research Areas:  

Cancer

KRAS G12D-IN-34 (Compound 13) is a KRAS (G12D) inhibitor with IC50 values for KRAS (G12D) and KRAS (WT) of 1.05 nM and 1.59 μM respectively. KRAS G12D-IN-34 can be used for research on non-small cell lung cancer .
loading...
    loading...
Cat. No.: HY-169908
CAS No.: 3055844-98-6
Target:  

STAT

Research Areas:  

Cancer

STAT3-IN-37 (Compound 101) is the inhibitor for STAT3 with an IC50 of 15 nM (measuring by DNA-HTRF assay) or 2 nM (measuring by human whole blood SOCS3 qPCR assay) .
loading...
    loading...
Cat. No.: HY-160585
CAS No.: 2753642-49-6
Target:  

PD-1/PD-L1

Research Areas:  

Inflammation/Immunology Cancer

PD-L1/PD-1-IN-1 (compound 8j) is a potent inhibitor of PD-L1/PD interaction, with IC50 < 1 nM. PD-L1/PD-1-IN-1 plays an important role in anti-tumor research .
loading...
    loading...
Cat. No.: HY-155507
CAS No.: 3040017-61-3
Target:  

c-Myc

Research Areas:  

Cancer

c-Myc inhibitor 11 (Compound 67e) is a c-MYC inhibitor (pEC50: 6.4). c-Myc inhibitor 11 has high clearance levels, moderate volume of distribution and short half-life in rat pharmacokinetic assay. c-Myc inhibitor 11 can be used for cancer research .
loading...
    loading...
Cat. No.: HY-179180
CAS No.: 2891831-40-4
Target:  

PD-1/PD-L1

Research Areas:  

Cancer

PD-1/PD-L1-IN-59 (Compound MZ51) is a PD-1/PD-L1 inhibitor with an IC50 of 183 nM. PD-1/PD-L1-IN-59 can be used for the study of triple-negative breast cancer (TNBC) .
loading...
    loading...
Cat. No.: HY-168582
CAS No.: 3058278-46-6
Target:  

Interleukin Related

Research Areas:  

Inflammation/Immunology

IL-17-IN-2 (Example 51) is a potent inhibitor of IL-17, with the IC50 of < 0.4 μM in HTRF and NHK assay .
loading...
    loading...
Cat. No.: HY-162544
CAS No.: 2893885-31-7
Target:  

PROTACs MAP4K

Research Areas:  

Cancer

PROTAC HPK1 Degrader-2 (compound 3) is a PROTAC degrader of HPK1, with the DC50 of 23 nM in human PBMC. PROTAC HPK1 Degrader-2 plays an important role in cancer research .
loading...
    loading...